Price
No data yet.
Social Signal Score
Company Profile
- CEO
- James Green
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- 0.00
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
VOGXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (4)
- Newsaccessnewswire.com·14d ago·Neutral
…versight as the Company scales operations following its August 2026 initial public offering RALEIGH, NC / ACCESS Newswire / September 22, 2026 / Vogenx, Inc. (Nasdaq:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced the appointment of Ken Toombs to its Board of Directors, effective September 21, 2026. Mr. Toombs will serve as an independent director and as Chair of the Audit Committee.
View source ↗ - Newsprnewswire.com·49d ago·Neutral
…stitutional Services LLC ("Jones") today announced that it served as sole book-running manager for the $81.3 million initial public offering of Vogenx, Inc. (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism. The offering consisted of 6,250,000 shares of Vogenx common stock at a public offering price of $13.00 per share, at the h…
View source ↗ - Newsaccessnewswire.com·53d ago·Negative
Vogenx Announces Closing of Initial Public Offering RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis, today announced the closing of its initial public offering of 6,250,000 shares of its common stock at …
View source ↗ - Newsaccessnewswire.com·55d ago·Negative
Vogenx Announces Pricing of Initial Public Offering RALEIGH, NC / ACCESS Newswire / August 11, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at
View source ↗
Earnings
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Sep 17$-0.07 vs $-0.07beat
Estimates and results for VOGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VOGX officers and directors.
No open-market trades in the recent filings. All 1 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VOGX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.